Simin Jamaly
Researcher
Job description
Member of the RNA and Molecular Pathology (RAMP) group .
Project Leader (PI) for the project with title of "Early Diagnosis of Chronic Kidney Disorders in Autoimmune Patients" funded by MABIT.
Holds a secondary position as a senior researcher at the Rheumatology Department, Oslo University Hospital (Rikshospitalet).
Work package leader at Health South-East RHF (Rikshospitalet) for the project "Biomarker Development for Early Diagnosis of Lupus Nephritis Using Liquid Biopsies."
Co-principal investigator in the European initiative LUpuS Inception-Cohort Developing (ELUCIDATE), a multi-national, multi-centric, prospective inception cohort for patients with systemic lupus erythematosus.
Has significant experience in study design and management of clinical trials related to biomarker development.
Collaborates with Beth Israel Deaconess Medical Center | BIDMC of Boston at Harvard Medical School, Karolinska Institutet in Sweden, and Aarhus University Hospital in Denmark.
The 50 latest publications is shown on this page. See all publications in Cristin here →
Research interests
At the RNA and Molecular Pathology (RAMP) research group, my primary focus is on the early detection and thorough monitoring of chronic kidney disorders, specifically lupus nephritis. I'm deeply invested in the development of a biomarker that could identify the presence of lupus nephritis even before tangible clinical symptoms, like proteinuria. Furthermore, I'm on a mission to craft a biomarker that could potentially eliminate the need for kidney biopsies, which are currently the golden and standard method for kidney disorders diagnosis. This urgency is amplified by the fact that about 20% of lupus nephritis patients undergo multiple biopsies to check the effectiveness of their treatments.
To achieve these goals, I'm engaged in several distinct projects. One of the standout initiatives, generously funded by MABIT, is "Early Diagnosis of Chronic Kidney Disorders in Autoimmune Patients." Within this project, I'm deeply exploring the avenues of personalized medicine and cutting-edge drug development. Alongside this, I'm serving as a full–time senior researcher at the Rheumatology Department of Rikshospitalet in Oslo. Here, I'm leading a prospective study that's slated to run from 2024 to 2026, aiming to closely monitor systemic lupus erythematosus (SLE) patients across various stages of their illness.
I've also played a key role in launching a multi-national, multi-center prospective cohort, specifically tailored for patients with SLE. Across all these endeavors, my commitment to rigorous study design and top-notch clinical trial management, particularly in the field of biomarker development, remains steadfast.
Member of research group
Member of project
Attachments:
- Simin Jamaly CV (pdf)